Search clinical trials for: Administration of ceralasertib and durvalumab

Total 147718 results

AstraZeneca

Recruiting

Ascending Doses of Ceralasertib in Combination With Chemotherapy and/or Novel Anti Cancer Agents

Adv Solid Malig - H&N SCC, ATM Pro / Def NSCLC, Gastric, Breast and Ovarian Cancer

Spain, United States, Belgium, United Kingdom, France, Hungary, Canada, Korea, Republic of, Australia
AstraZeneca

Active, not recruiting

A Study to Evaluate the Safety and Pharmacokinetics of Ceralasertib in Combination With Durvalumab in Chinese Patients With Advanced Solid Tumours

Advanced Solid Tumours

China
AstraZeneca

Active, not recruiting

A Study to Investigate Efficacy and Safety of Ceralasertib Plus Durvalumab in Participants Aged ≥ 18 Years With Advanced or Metastatic Non-small Cell Lung Cancer Whose Disease Progressed on or After Prior Anti-PD-(L)1 Therapy and Platinum-based Chemotherapy (LOTOS)

Advanced or Metastatic NSCLC

Russian Federation
AstraZeneca

Active, not recruiting

A Study of Ceralasertib Monotherapy and Ceralasertib Plus Durvalumab in Patients With Melanoma and Resistance to PD-(L)1 Inhibition (MONETTE)

Melanoma

France, Germany, Italy, Spain, Belgium, Canada, Poland, Korea, Republic of, United Kingdom, United States, Australia
AstraZeneca
Parexel

Active, not recruiting

A Phase III Study of Ceralasertib Plus Durvalumab Versus Docetaxel in Patients With Non Small Cell Lung Cancer (NSCLC) Whose Disease Progressed On or After Prior Anti PD (L)1 Therapy And Platinum Based Chemotherapy (LATIFY)

Advanced or Metastatic Non-Small Cell Lung Cancer

United States, France, Italy, Spain, Belgium, Romania, Canada, Korea, Republic of, Brazil, Hungary, Japan, China, Taiwan, Hong Kong, United Kingdom, Germany, Poland, Australia, Netherlands, Serbia, India, Argentina, Ireland
Assistance Publique Hopitaux De Marseille

Active, not recruiting

Precision Immuno-Oncology for Advanced Non-small Cell Lung Cancer Patients With PD-1 ICI Resistance (PIONeeR)

Non-small Cell Lung Cancer

France
AstraZeneca

Active, not recruiting

Phase II Umbrella Study of Novel Anti-cancer Agents in Patients With NSCLC Who Progressed on an Anti-PD-1/PD-L1 Containing Therapy (HUDSON)

Non-Small Cell Lung Cancer

France, Spain, United States, Canada, Korea, Republic of, Austria, Israel, Germany
Muhammad Furqan
AstraZeneca

Recruiting

Chemo-Immunotherapy Followed by Durvalumab and Ceralasertib in Treatment Naïve Patients With Extensive Stage Small Cell Lung Cancer

Extensive Stage Small Cell Lung Cancer

United States
IFOM ETS - The AIRC Institute of Molecular Oncology
AstraZeneca

Recruiting

Restoring Sensitivity To Immunotherapy In Advanced Triple Negative Breast Cancer Exploiting Ceralasertib Priming Followed By Combined Durvalumab/Nab-Paclitaxel (ATRiBRAVE)

Triple Negative Breast Cancer Metastatic

Italy
University of Leeds
University College London Hospitals; The Leeds Teaching Hospitals NHS Trust; University... and other collaborators

Recruiting

A Platform Study of Novel Agents in Combination With Radiotherapy in NSCLC (CONCORDE)

Non Small Cell Lung Cancer

United Kingdom
University Medical Center Groningen
Erasmus Medical Center

Completed

Precision Thyroid Cancer Surgery With Molecular Fluorescent Guided Imaging (TARGET)

Papillary Thyroid Cancer | Lymph Node Metastases

Netherlands
Acerta Pharma BV

Active, not recruiting

A Study of AZD6738 and Acalabrutinib in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)

Chronic Lymphocytic Leukemia

United Kingdom, Poland
BiondVax Pharmaceuticals ltd.

Completed

A Study to Assess the Safety and Immunogenicity of M-001 Influenza Vaccine as a Primer to TIV in Elderly Volunteers

Healthy | Influenza

Israel
University of Colorado, Denver

Withdrawn

Assessing the Combination of Durvalumab (MEDI4736) and Trabectedin in Solid Tumors

Solid Tumor, Adult
University of Texas Southwestern Medical Center
AstraZeneca

Active, not recruiting

Phase II Concurrent Durvalumab and Radiotherapy for for Stage III Non-Small Cell Lung Cancer

Non Small Cell Lung Cancer | Lung Cancer Stage III

United States
MedImmune LLC

Completed

Durvalumab Alone or in Combination With Novel Agents in Subjects With NSCLC (COAST)

Stage III Non-small Cell Lung Cancer | Unresectable

United States, Canada, Italy, Spain, France, Hong Kong, Portugal, Taiwan, Poland
AstraZeneca

Completed

A Phase 1/2 Study of Durvalumab(MEDI4736) and Tremelimumab in Chinese Patients With Advanced Malignancies

Advanced Malignancy

China
AstraZeneca
Kappa Santé

Recruiting

A French Real-life Study: EvaluatioN of durvALumab Utilization and Effectiveness for First Line Extensive Stage Small Cell Lung Cancer. (ARSENAL)

Small Cell Lung Carcinoma

France
Yonsei University

Recruiting

Concurrent Neoadjuvant Chemoradiotherapy Plus Durvalumab (MEDI4736) in Resectable Stage III NSCLC

Potentially Resectable Stage II/IIIa NSCLC

Korea, Republic of
AstraZeneca

Completed

An Open-Label, Multi-Centre, Study to Assess the Safety of Fixed-Dose Durvalumab + Tremelimumab Combination Therapy or Durvalumab Monotherapy in Advanced Solid Malignancies. (STRONG)

Advanced Solid Malignancies

United States, Germany, Italy, United Kingdom, Canada, France, Korea, Republic of, Netherlands
Dana-Farber Cancer Institute
AstraZeneca; Osteosarcoma Institute

Recruiting

Olaparib With Ceralasertib in Recurrent Osteosarcoma

Osteosarcoma | Osteosarcoma Recurrent

United States
University of Michigan Rogel Cancer Center

Active, not recruiting

Targeting Resistant Prostate Cancer With ATR and PARP Inhibition (TRAP Trial)

Prostate Cancer

United States
Hark Kyun Kim

Recruiting

Vactosertib and Durvalumab in Gastric Cancer

Stomach Neoplasm

Korea, Republic of
Academic Thoracic Oncology Medical Investigators...
AstraZeneca

Completed

A Clinical Trial of Durvalumab (MEDI4736) as 1st Line Therapy in Advanced Non-small Cell Lung Cancer Patients

Non-Small Cell Lung Cancer NSCLC

United States
Yonsei University

Completed

A Study of Pazopanib and Durvalumab for Metastatic Soft Tissue Sarcoma

Sarcoma

Korea, Republic of
NSABP Foundation Inc

Completed

Study of Durvalumab (MEDI4736) After Chemo-Radiation for Microsatellite Stable Stage II-IV Rectal Cancer

Rectal Cancer

United States
AstraZeneca

Active, not recruiting

Durvalumab and Tremelimumab for Pediatric Malignancies

Pediatric Cancer | Hematological Malignancies | Solid Tumor Pediatric

Spain, Italy, United States, United Kingdom, France, Netherlands, Germany
Korea United Pharm. Inc.

Active, not recruiting

Study to Evaluate the Safety and PK of UI018

Hyperlipemia, Mixed

Korea, Republic of
Assistance Publique - Hôpitaux de Paris
AstraZeneca

Recruiting

Durvalumab/Tremelimumab in Neoadjuvant and Adjuvant Setting in Patients With HCC Treated by Electroporation Ablation (DUMELEP)

BCLC A Hepatocellular Carcinoma Non-resectable and Not Amenable for RFA

France
MedImmune LLC

Withdrawn

Novel Oncology Therapies in Combination With Adjuvant Chemo in High-risk MSS-CRC

Microsatellite-stable Colorectal Cancer
Yonsei University

Not yet recruiting

Window of Opportunity Trial of Durvalumab (MEDI4736) to Identify Immune Dynamics in Operable Non-small Cell Lung Cancer (NSCLC) (MIRACLE)

Non Small Cell Lung Cancer

Korea, Republic of
Oslo University Hospital
AstraZeneca

Active, not recruiting

Durvalumab(MEDI4736) After chemoRadioTherapy(DART) for NSCLC-a Translational and Biomarker Study (DART)

Cancer | NSCLC | Non Small Cell Lung Cancer | NSCLC, Stage III | Non Small Cell Lung Cancer Stage III

Norway, Finland, Lithuania, Estonia
MedImmune LLC

Completed

IPH5201 as Monotherapy or in Combination With Durvalumab +/- Oleclumab in Subjects With Advanced Solid Tumors.

Advanced Solid Tumors

United States, France, Spain, Switzerland
Leo Mascarenhas

Completed

Durvalumab in Pediatric and Adolescent Patients

Lymphoma | Solid Tumor | Central Nervous System Tumors

United States
John L. Villano, MD, PhD

Active, not recruiting

Durvalumab and Tremelimumab Combination in Somatically Hypermutated Recurrent Solid Tumors

Tumor, Solid

United States
Swiss Group for Clinical Cancer Research

Active, not recruiting

Neoadjuvant and Adjuvant Durvalumab in Combination With Neoadjuvant Chemotherapy in Patients With Operable Urothelial Cancer. (SAKK 06/17)

Urothelial Cancer

Germany, Switzerland
AstraZeneca

Completed

A Study to Investigate Biomarker Effects of Pre-Surgical Treatment With DNA Damage Repair (DDR) Agents in Patients With Head and Neck Squamous Cell Carcinoma (HNSCC).

Head and Neck Squamous Cell Carcinoma

Taiwan, United States, France
ETOP IBCSG Partners Foundation
AstraZeneca AG Switzerland

Not yet recruiting

A Study to Evaluate the Benefit of Adding Durvalumab After Chemotherapy, Durvalumab and Surgery in Patients With Early-stage, Operable, Non-small Cell Lung Cancer. (ADOPT-lung)

Non Small Cell Lung Cancer
AstraZeneca

Active, not recruiting

A Phase 3b, Open-label, Multi-center Study on Durvalumab in Combination With Gemcitabine-based Chemotherapy as 1L Treatment for the Chinese Patients With Unresectable Biliary Tract Cancers (BTC) (TopDouble)

Biliary Tract Cancers

China
Institut Claudius Regaud

Active, not recruiting

A Trial Evaluating Stereotactic Radiotherapy Plus Durvalumab Continuation for Patients With NSCLC Metachronous Oligometastatic Disease Under Durvalumab Consolidation Following Chemoradiation (SILK BM)

NSCLC

France
AstraZeneca

Completed

Study of AZD9150 and MEDI4736 (Durvalumab) in Japanese Adult Patients With Advanced Solid Malignancies

Advanced Solid Malignancies

Japan
Biocity Biopharmaceutics Co., Ltd.

Not yet recruiting

BC3402 in Combination With Durvalumab in Patients With Advanced Hepatocellular Carcinoma

Hepatocellular Carcinoma

China
Memorial Sloan Kettering Cancer Center
AstraZeneca; MedImmune LLC

Active, not recruiting

RAI Plus Immunotherapy for Recurrent/Metastatic Thyroid Cancers

Thyroid Cancer

United States
Canadian Cancer Trials Group
AstraZeneca

Active, not recruiting

Durvalumab With or Without Tremelimumab in Advanced Incurable Solid Malignancies Given With or Without Standard Chemotherapy Regimens

Solid Malignancies

Canada
ARCAGY/ GINECO GROUP
AstraZeneca

Active, not recruiting

Immunotherapy With Neo-adjuvant Chemotherapy for OVarian Cancer (INeOV)

Ovarian Cancer

France
Washington University School of Medicine
National Cancer Institute (NCI); National Institutes of Health (NIH); MedImmune...

Terminated

Neoantigen DNA Vaccine Alone vs. Neoantigen DNA Vaccine Plus Durvalumab in Triple Negative Breast Cancer Patients Following Standard of Care Therapy

Triple Negative Breast Cancer | Triple Negative Breast Neoplasms | TNBC - Triple-Negative Breast Cancer | Triple-negative Breast Carcinoma

United States
Grupo Espanol Multidisciplinario del Cancer Digestivo
AstraZeneca; Vall d'Hebron Institute of Oncology (VHIO)

Recruiting

Durvalumab (MEDI4736) Plus Total Neoadjuvant Therapy (TNT) in Locally Advanced Rectal Cancer (DUREC)

Rectal Cancer

Spain
Institut Cancerologie de l'Ouest
AstraZeneca

Active, not recruiting

Prostate Cancer With OligometaSTatic Relapse: Combining Stereotactic Ablative Radiotherapy and Durvalumab (MEDI4736) (POSTCARD)

Bone Metastases | Prostate Cancer Patients | Node; Prostate

France
Korea United Pharm. Inc.

Completed

A Study to Compare PK, PD and Safety of UI058 and UIC202004 in Healthy Subjects

GERD

Korea, Republic of
ADC Therapeutics S.A.

Terminated

Safety and Antitumor Activity Study of Loncastuximab Tesirine and Durvalumab in Diffuse Large B-Cell, Mantle Cell, or Follicular Lymphoma

Follicular Lymphoma | Diffuse Large B-Cell Lymphoma | Mantle Cell Lymphoma

Spain, United States

Search clinical trials for: Administration of ceralasertib and durvalumab

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Hungary

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations